Compass Therapeutics is a biopharmaceutical company focused on oncology and developing antibody-based therapeutics to treat human diseases. The company has several product candidates in the clinical stage of development, including CTX-009 and CTX-471, which are bispecific and monoclonal antibodies respectively. Founded in 2014 and based in Boston, Massachusetts, Compass Therapeutics is committed to finding treatments for critical diseases.